Enlighten: Research Data

In this section

Clinical, Biorepository and Research Datasets for HCV Research UK

McLauchlan, J. , Irving, W. and McDonald, S. (2022) Clinical, Biorepository and Research Datasets for HCV Research UK. [Data Collection]

Datacite DOI: 10.5525/gla.researchdata.1254

Related Enlighten Publications

Cohort profile: the hepatitis C virus (HCV) research UK clinical database and biobank
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
Response to DAA therapy in the NHS England early access programme for rare HCV subtypes from low and middle income countries
Real-world outcomes of DAA treatment and retreatment in UK-based patients infected with HCV genotypes/subtypes endemic in Africa
Human Endogenous Retrovirus-K HML-2 integration within RASGRF2 is associated with intravenous drug abuse and modulates transcription in a cell-line model
Comparison of next-generation sequencing technologies for the comprehensive assessment of full-length hepatitis C viral genomes
The rs429358 locus in apolipoprotein E is associated with hepatocellular carcinoma in patients with cirrhosis

Not all data is available to download from this page. Usually this is because the dataset is too large or it is restricted in some way.

Collection description

HCV Research UK is a consortium of clinical and scientific researchers from across the UK, which has recruited approximately 12,000 individuals who were infected with hepatitis C virus (HCV). Individuals gave consent for their data and samples to be utilised for research purposes. The clinical, sample and research data are held in individual databases that are linked by an overarching application that allows selection of data based on an extensive range of clinical phenotypes and demographics. Applications for access to data and/or samples is required for approval of release; all applications are considered by the HCV Research UK Tissue and Data Access Committee (TDAC). Following approval, a formal agreement is agreed between the University of Glasgow (the Managing Party for HCV Research UK) and institutions representing the applicant(s). Access to data and samples also requires costs to be covered for preparing data and selecting samples.

Funding: